287 related articles for article (PubMed ID: 33128347)
1. Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Merkel PA; Niles J; Jimenez R; Spiera RF; Rovin BH; Bomback A; Pagnoux C; Potarca A; Schall TJ; Bekker P;
ACR Open Rheumatol; 2020 Nov; 2(11):662-671. PubMed ID: 33128347
[TBL] [Abstract][Full Text] [Related]
2. Journal Club Review of "Avacopan for the Treatment of ANCA-Associated Vasculitis".
Soulsby WD
ACR Open Rheumatol; 2022 Jul; 4(7):558-561. PubMed ID: 35167187
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial.
Merkel PA; Jayne DR; Wang C; Hillson J; Bekker P
JMIR Res Protoc; 2020 Apr; 9(4):e16664. PubMed ID: 32088663
[TBL] [Abstract][Full Text] [Related]
4. Avacopan for the Treatment of ANCA-Associated Vasculitis.
Jayne DRW; Merkel PA; Schall TJ; Bekker P;
N Engl J Med; 2021 Feb; 384(7):599-609. PubMed ID: 33596356
[TBL] [Abstract][Full Text] [Related]
5. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.
Jayne DRW; Bruchfeld AN; Harper L; Schaier M; Venning MC; Hamilton P; Burst V; Grundmann F; Jadoul M; Szombati I; Tesař V; Segelmark M; Potarca A; Schall TJ; Bekker P;
J Am Soc Nephrol; 2017 Sep; 28(9):2756-2767. PubMed ID: 28400446
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial.
Geetha D; Dua A; Yue H; Springer J; Salvarani C; Jayne D; Merkel P;
Ann Rheum Dis; 2024 Jan; 83(2):223-232. PubMed ID: 37979959
[TBL] [Abstract][Full Text] [Related]
7. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial.
Strand V; Jayne DRW; Horomanski A; Yue H; Bekker P; Merkel PA;
Lancet Rheumatol; 2023 Aug; 5(8):e451-e460. PubMed ID: 38251577
[TBL] [Abstract][Full Text] [Related]
8. Avacopan for the Treatment of Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis.
Alihosseini C; Kopelman H; Zaino M; Feldman SR
Ann Pharmacother; 2023 Dec; 57(12):1449-1454. PubMed ID: 36975183
[TBL] [Abstract][Full Text] [Related]
9. How the Availability of Anti-C5a Agents Could Change the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Roccatello D; Fenoglio R; Oddone V; Sciascia S
Kidney Blood Press Res; 2022; 47(8):506-513. PubMed ID: 35665698
[TBL] [Abstract][Full Text] [Related]
10. Avacopan, a Novel Competitive C5a Receptor Antagonist, for Severe Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis.
Nguyen ID; Sinnathamby ES; Mason J; Urban B; Neuchat EE; Wenger DM; Ahmadzadeh S; Shekoohi S; Kaye AD
Clin Drug Investig; 2023 Aug; 43(8):595-603. PubMed ID: 37596445
[TBL] [Abstract][Full Text] [Related]
11. Glucocorticoid Toxicity Index scores by domain in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with avacopan versus standard prednisone taper: post-hoc analysis of data from the ADVOCATE trial.
Patel NJ; Jayne DRW; Merkel PA; Bekker P; Zhang Y; Yue H; Stone JH
Lancet Rheumatol; 2023 Mar; 5(3):e130-e138. PubMed ID: 38251609
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
[TBL] [Abstract][Full Text] [Related]
13. Real-World Experience With Avacopan in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis.
Zonozi R; Aqeel F; Le D; Cortazar FB; Thaker J; Zabala Ramirez MJ; Sattui Cortes SE; Attieh RM; Chung M; Bulbin DH; Shaikh A; Guaman K; Ford J; Diffie C; Gewurz-Singer O; Sauvage G; Jeyabalan A; Geara A; Ayoub I; Bomback A; Khoury LL; George JC; Jhaveri KD; Derebail VK; Niles JL; Geetha D
Kidney Int Rep; 2024 Jun; 9(6):1783-1791. PubMed ID: 38899183
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacological and clinical profiles of avacopan (TAVNEOS
Maruyama Y; Yoshida T; Maruyama I
Nihon Yakurigaku Zasshi; 2023 Sep; 158(5):399-407. PubMed ID: 37460300
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of avacopan in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: A subanalysis of a randomized Phase 3 study.
Harigai M; Kaname S; Tamura N; Dobashi H; Kubono S; Yoshida T
Mod Rheumatol; 2023 Mar; 33(2):338-345. PubMed ID: 35482532
[TBL] [Abstract][Full Text] [Related]
16. Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan.
Cortazar FB; Niles JL; Jayne DRW; Merkel PA; Bruchfeld A; Yue H; Schall TJ; Bekker P;
Kidney Int Rep; 2023 Apr; 8(4):860-870. PubMed ID: 37069984
[TBL] [Abstract][Full Text] [Related]
17. Avacopan, a selective C5a receptor antagonist, for anti-neutrophil cytoplasmic antibody-associated vasculitis.
Harigai M; Takada H
Mod Rheumatol; 2022 Apr; 32(3):475-483. PubMed ID: 34984461
[TBL] [Abstract][Full Text] [Related]
18. C5a receptor inhibitor avacopan in immunoglobulin A nephropathy-an open-label pilot study.
Bruchfeld A; Magin H; Nachman P; Parikh S; Lafayette R; Potarca A; Miao S; Bekker P
Clin Kidney J; 2022 May; 15(5):922-928. PubMed ID: 35498891
[TBL] [Abstract][Full Text] [Related]
19. Avacopan in the treatment of ANCA-associated vasculitis.
Tesar V; Hruskova Z
Expert Opin Investig Drugs; 2018 May; 27(5):491-496. PubMed ID: 29718732
[TBL] [Abstract][Full Text] [Related]
20. Gradual increase of avacopan dose with concomitant ursodeoxycholic acid use may help avoid the risk of C5a receptor inhibitor-induced liver injury in antineutrophil cytoplasmic antibody-associated vasculitis.
Kataoka H; Tomita T; Nakanowatari M; Kondo M; Mukai M
Mod Rheumatol Case Rep; 2023 Jun; 7(2):444-447. PubMed ID: 36972244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
